Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

  • Massanella, Marta|||0000-0002-3326-151X
  • Ouchi, Dan|||0000-0002-8630-152X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Buzón, Maria José|||0000-0003-4427-9413
  • Richman, Douglas D.
  • Orna, Elisa|||0000-0002-6862-9636
  • Stevenson, Mario
  • Gatell, José Mª|||0000-0002-4705-3244
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
Background: HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART with raltegravir reduced CD8 T-cell activation in the Discor-Ral and IntegRal studies, we have evaluated the effect of raltegravir intensification on several soluble inflammation markers in these studies. Methods: Longitudinal plasma samples (0-48 weeks) from the IntegRal (n=67, 22 control and 45 intensified individuals) and the Discor-Ral studies (44 individuals with CD4 T-cell counts,350 cells/μl, 14 control and 30 intensified) were assayed for 25 markers. Mann-Whitney, Wilcoxon, Spearman test and linear mixed models were used for analysis. Results: At baseline, different inflammatory markers were strongly associated with HCV co-infection, lower CD4 counts and with cART regimens (being higher in PI-treated individuals), but poorly correlated with detection of markers of residual viral replication. Although raltegravir intensification reduced inflammation in individuals with lower CD4 T-cell counts, no effect of intensification was observed on plasma markers of inflammation in a global analysis. An association was found, however, between reductions in immune activation and plasma levels of the coagulation marker D-dimer, which exclusively decreased in intensified patients on protease inhibitor (PI)-based cART regimens (P=0.040). Conclusions: The inflammatory profile in treated HIV-infected individuals showed a complex association with HCV co-infection, the levels of CD4 T cells and the cART regimen. Raltegravir intensification specifically reduced D-dimer levels in PI-treated patients, highlighting the link between cART composition and residual viral replication; however, raltegravir had little effect on other inflammatory markers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery

  • Massanella Luna, Marta, 1983-
  • Gomez, Elisabet|||0000-0002-9779-5940
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Curriu Martí, Marta
  • Ouchi, Dan|||0000-0002-8630-152X
  • Puig, Jordi|||0000-0002-4075-0346
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
BACKGROUND: High levels of ex vivo CD4 T-cell death and the accumulation of highly differentiated and/or immunosenescent T cells have been associated with poor CD4 T-cell recovery in treated HIV-infected individuals. However, the relationship between cell death and T-cell differentiation is still unclear. METHODS: We have analyzed cell death, immunosenescence and differentiation parameters in HAART-treated subjects (VL <50 copies/mL for more than 2 years) with CD4 T-cell count <350 cells/μL (immunodiscordant, n = 23) or.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hidden costs of antiretroviral treatment, the public health efficiency of drug packaging

  • Andreu-Crespo, Àngels
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Cardona Peitx, Gloria
  • Sala-Piñol, Ferran
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Bonafont-Pujol, Xavier
While the overall percentage of unused antiretroviral medicines returned to the hospital pharmacy is low, their cost is quite high. Adverse events, treatment failure, pharmacokinetic interactions, pregnancy, or treatment simplification are common reasons for unplanned treatment changes. Socially inefficient antiretroviral packages prevent the reuse of drugs returned to the hospital pharmacy. We defined antiretroviral package categories based on the excellence of drug packaging and analyzed the number of pills and costs of drugs returned during a period of 1 year in a hospital-based HIV unit attending to 2,413 treated individuals. A total of 6,090 pills (34% of all returned antiretrovirals) - with a cost of 47,139.91€ - would be totally lost, mainly due to being packed up in the lowest efficiency packages. Newer treatments are packaged in low-excellence categories of packages, thus favoring the maintenance of these hidden costs in the near future. Therefore, costs of this low-efficiency drug packaging, where medication packages are started but not completed, in high-cost medications are substantial and should be properly addressed. Any improvement in the packaging by the manufacturer, and favoring the choice of drugs supplied through efficient packages (when efficacy, toxicity, and convenience are similar), should minimize the treatment expenditures paid by national health budgets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gp high cells and correlates with HIV-1 viral load

  • Minuesa, Gerard|||0000-0001-9911-8428
  • Arimany-Nardi, Cristina
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Moltó Marhuenda, José
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
To evaluate the role of P-glycoprotein (P-gp) and multidrug-resistant-protein 1 (MRP1) on raltegravir intracellular drug disposition in CD4+ T cells, investigate the effect of HIV-1 infection on P-gp expression and correlate HIV-1 viraemia with P-gp activity in primary CD4+ T cell subsets. The cellular accumulation ratio of [ 3 H]raltegravir was quantified in CD4+ T cell lines overexpressing either P-gp (CEM-P-gp) or MRP1 (CEM-MRP1) and in primary CD3+CD4+ T cells with high (P-gp high) and low P-gp activity (P-gp low); inhibition of efflux transporters was confirmed by the intracellular retention of calcein-AM. The correlation of P-gp activity with HIV-1 viraemia was assessed in naive and memory T cell subsets from 21 HIV-1-infected treatment-naive subjects. [ 3 H]Raltegravir cellular accumulation ratio decreased in CEM-P-gp cells (P < 0.0001). XR9051 (a P-gp inhibitor) and HIV-1 PIs reversed this phenomenon. Primary CD4+P-gp high cells accumulated less raltegravir (38.4% ± 9.6%) than P-gp low cells, whereas XR9051 also reversed this effect. In vitro HIV-1 infection of PBMCs and stimulation of CD4+ T cells increased P-gp mRNA and P-gp activity, respectively, while primary CD4+P-gp high T cells sustained a higher HIV-1 replication than P-gp low cells. A significant correlation between HIV-1 viraemia and P-gp activity was found in different CD4+ T cell subsets, particularly memory CD4+ T cells (r = 0.792, P < 0.0001). Raltegravir is a substrate of P-gp in CD4+ T cells. Primary CD4+P-gp high T cells eliminate intracellular raltegravir more readily than P-gp low cells and HIV-1 viraemia correlates with P-gp overall activity. Specific CD4+P-gp high T cell subsets could facilitate the persistence of viral replication in vivo and ultimately promote the appearance of drug resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Oral microbiome in HIV-associated periodontitis

  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Peterson, Jessica
  • Reznik, David
  • Harris, Erica V.
  • Joseph, Sandeep J.
  • Rivera, Javier
  • Kannanganat Sidharthan, Sunil|||0000-0003-4605-9799
  • Amara, Rama
  • Nguyen, Minh Ly
  • Mutembo, Simon
  • Paredes, Roger|||0000-0002-6553-691X
  • Read, Timothy D.
  • Marconi, Vincent C.
Supplemental Digital Content is available in the text HIV-associated periodontal diseases (PD) could serve as a source of chronic inflammation. Here, we sought to characterize the oral microbial signatures of HIV+ and HIV- individuals at different levels of PD severity. This cross-sectional study included both HIV+ and HIV- patients with varying degrees of PD. Two tooth, 2 cheek, and 1 saliva samples were obtained for microbiome analysis. Mothur/SILVADB were used to classify sequences. R/Bioconductor (Vegan, PhyloSeq, and DESeq2) was employed to assess overall microbiome structure differences and differential abundance of bacterial genera between groups. Polychromatic flow cytometry was used to assess immune activation in CD4 and CD8 cell populations. Around 250 cheek, tooth, and saliva samples from 50 participants (40 HIV+ and 10 HIV-) were included. Severity of PD was classified clinically as None/Mild (N), Moderate (M), and Severe (S) with 18 (36%), 16 (32%), and 16 (32%) participants in each category, respectively. Globally, ordination analysis demonstrated clustering by anatomic site (R 2 = 0.25, P < 0.001). HIV status and PD severity showed a statistically significant impact on microbiome composition but only accounted for a combined 2% of variation. HIV+ samples were enriched in genera Abiotrophia, Neisseria, Kingella, and unclassified Neisseriaceae and depleted in Leptotrichia and Selenomonas. The Neisseria genus was consistently enriched in HIV+ participants regardless of sampling site and PD level. Immune markers were altered in HIV+ participants but did not show association with the oral microbiome. HIV-associated changes in oral microbiome result in subtle microbial signatures along different stages of PD that are common in independent oral anatomic sites.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A baseline metabolomic signature is associated with immunological CD4 + T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Mallol, Roger
  • López Dupla, Miguel
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Blanco, Julià|||0000-0002-2225-0217
  • Cañellas, Nicolau
  • Rull, Anna|||0000-0002-8907-7754
  • Leal, Manuel
  • Correig, Xavier|||0000-0002-6902-3054
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Vidal, Francesc|||0000-0002-6692-6186
Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma HIV-1 Tropism and the Risk of Short- Term Clinical Progression to AIDS or Death

  • Casadellà, Maria|||0000-0002-4115-2305
  • Cozzi-Lepri, Alessandro|||0000-0002-6339-919X
  • Phillips, Andrew
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Bickel, Markus
  • Sedlacek, Dalibor
  • Zilmer, Kai
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Lundgren, Jens|||0000-0001-8901-7850
  • Paredes, Roger|||0000-0002-6553-691X
Objective. To investigate if plasma HIV-1 tropism testing could identify subjects at higher risk for clinical progression and death in routine clinical management. Design. Nested case-control study within the EuroSIDA cohort. Methods. Cases were subjects with AIDS or who died from any cause, with a plasma sample with HIV-1 RNA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Balances, a New Perspective for Microbiome Analysis

  • Rivera Pinto, Javier|||0000-0002-4427-6442
  • Egozcue, Juan José|||0000-0002-5144-4483
  • Pawlowsky-Glahn, Vera|||0000-0001-9775-6434
  • Paredes, Roger|||0000-0002-6553-691X
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Calle, M. Luz|||0000-0001-9334-415X
We propose a new algorithm for the identification of microbial signatures. These microbial signatures can be used for diagnosis, prognosis, or prediction of therapeutic response based on an individual's specific microbiota. High-throughput sequencing technologies have revolutionized microbiome research by allowing the relative quantification of microbiome composition and function in different environments. In this work we focus on the identification of microbial signatures, groups of microbial taxa that are predictive of a phenotype of interest. We do this by acknowledging the compositional nature of the microbiome and the fact that it carries relative information. Thus, instead of defining a microbial signature as a linear combination in real space corresponding to the abundances of a group of taxa, we consider microbial signatures given by the geometric means of data from two groups of taxa whose relative abundances, or balance, are associated with the response variable of interest. In this work we present selbal, a greedy stepwise algorithm for selection of balances or microbial signatures that preserves the principles of compositional data analysis. We illustrate the algorithm with 16S rRNA abundance data from a Crohn's microbiome study and an HIV microbiome study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Urrea, Víctor|||0000-0002-2577-856X
  • Dalmau, Judith|||0000-0001-7513-3711
  • Lopez, Miguel
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Ouchi, Dan|||0000-0002-8630-152X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Passaes, Caroline|||0000-0002-0813-2521
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Saez-Cirion, Asier
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Esteller, M.|||0000-0003-4490-6093
  • Berdasco, Maria|||0000-0002-6750-0400
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
BACKGROUND: Human genetic variation-mostly in the human leukocyte antigen (HLA) and C-C chemokine receptor type 5 (CCR5) regions-explains 25% of the variability in progression of human immunodeficiency virus (HIV) infection. However, it is also known that viral infections can modify cellular DNA methylation patterns. Therefore, changes in the methylation of cytosine-guanine (CpG) islands might modulate progression of HIV infection. METHODS: In total, 85 samples were analyzed: 21 elite controllers (EC), 21 subjects with HIV before combination antiretroviral therapy (cART) (viremic, 93 325 human immunodeficiency virus type 1 [HIV-1] RNA copies/mL) and under suppressive cART (cART, median of 17 months, <50 HIV-1 RNA copies/mL), and 22 HIV-negative donors (HIVneg). We analyzed the methylation pattern of 485 577 CpG in DNA from peripheral CD4+ T lymphocytes. We selected the most differentially methylated gene (TNF) and analyzed its specific methylation, messenger RNA (mRNA) expression, and plasma protein levels in 5 individuals before and after initiation of cART. RESULTS: We observed 129 methylated CpG sites (associated with 43 gene promoters) for which statistically significant differences were recorded in viremic versus HIVneg, 162 CpG sites (55 gene promoters) in viremic versus cART, 441 CpG sites (163 gene promoters) in viremic versus EC, but none in EC versus HIVneg. The TNF promoter region was hypermethylated in viremic versus HIVneg, cART, and EC. Moreover, we observed greater plasma levels of TNF in viremic individuals than in EC, cART, and HIVneg. CONCLUSIONS: Our study shows that genome methylation patterns vary depending on HIV infection status and progression profile and that these variations might have an impact on controlling HIV infection in the absence of cART.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers

  • Vesterbacka, Jan
  • Rivera, Javier
  • Noyan, Kajsa
  • Parera, Mariona|||0000-0002-0756-8307
  • Neogi, Ujjwal
  • Calle, M. Luz|||0000-0001-9334-415X
  • Paredes, Roger|||0000-0002-6553-691X
  • Sönnerborg, Anders
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Nowak, Piotr|||0000-0003-2747-0734
Gut microbiota dysbiosis features progressive HIV infection and is a potential target for intervention. Herein, we explored the microbiome of 16 elite controllers (EC), 32 antiretroviral therapy naive progressors and 16 HIV negative controls. We found that the number of observed genera and richness indices in fecal microbiota were significantly higher in EC versus naive. Genera Succinivibrio, Sutterella, Rhizobium, Delftia, Anaerofilum and Oscillospira were more abundant in EC, whereas Blautia and Anaerostipes were depleted. Additionally, carbohydrate metabolism and secondary bile acid synthesis pathway related genes were less represented in EC. Conversely, fatty acid metabolism, PPAR-signalling and lipid biosynthesis proteins pathways were enriched in EC vs naive. The kynurenine pathway of tryptophan metabolism was altered during progressive HIV infection, and inversely associated with microbiota richness. In conclusion, EC have richer gut microbiota than untreated HIV patients, with unique bacterial signatures and a distinct metabolic profile which may contribute to control of HIV.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4 + T-cell immune recovery

  • Gomez, Elisabet|||0000-0002-9779-5940
  • García Rodríguez, Elisabet
  • Urrea, Víctor|||0000-0002-2577-856X
  • Massanella, Marta|||0000-0002-3326-151X
  • Puig, Jordi|||0000-0002-4075-0346
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
Poor CD4 + T-cell recovery after cART has been associated with skewed T-cell maturation, inflammation and immunosenescence; however, T-cell functionality in those individuals has not been fully characterized. In the present study, we assessed T-cell function by assessing cytokine production after polyclonal, CMV and HIV stimulations of T-cells from ART-suppressed HIV-infected individuals with CD4 + T-cell counts.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4 + T-cell immune recovery

  • Gomez, Elisabet|||0000-0002-9779-5940
  • Massanella, Marta|||0000-0002-3326-151X
  • García Rodríguez, Elisabet
  • Giles, David
  • Bernadó, Marta
  • Urrea, Víctor|||0000-0002-2577-856X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Ouchi, Dan|||0000-0002-8630-152X
  • Puig, Jordi|||0000-0002-4075-0346
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
Some HIV-infected c-ART-suppressed individuals show incomplete CD4 + T-cell recovery, abnormal T-cell activation and higher mortality. One potential source of immune activation could be coinfection with cytomegalovirus (CMV). IgG and IgM levels, immune activation, inflammation and T-cell death in c-ART-suppressed individuals with CD4 + T-cell counts.